Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04844073 | A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer | terminated | Phase 1 / Phase 2 | 95 | TakedaINDUSTRY | 4 | Sep 24, 2026 | clinicaltrials |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 62 | Hoffmann-La RocheINDUSTRY | 6 | Sep 15, 2026 | clinicaltrials |
| NCT00642603 | A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer | terminated | Phase 2 | 41 | Hoffmann-La RocheINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05435014 | T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | T-ACE Medical Co., LtdINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05286827 | Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05572684 | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 97 | NextCure, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05199285 | A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab | terminated | Phase 2 | 15 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03695250 | BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 8 | Edward KimOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.(FORTITUDE-103) | terminated | Phase 1 / Phase 2 | 72 | AmgenINDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT00640978 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05731947 | Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 41 | Syndax PharmaceuticalsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04251715 | mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma | terminated | Phase 2 | 5 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | terminated | Phase 2 | 43 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer(Neo-POLEM) | terminated | Phase 2 | 3 | University of SouthamptonOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | terminated | Phase 2 | 7 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 2 | May 14, 2026 | clinicaltrials |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | terminated | Phase 2 | 8 | University of CincinnatiOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | May 5, 2026 | clinicaltrials |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | terminated | Phase 2 | 6 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers(TEJAS-2) | terminated | Phase 2 | 29 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | terminated | Phase 1 / Phase 2 | 2 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05518110 | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer(PaTcH) | terminated | Phase 2 | 20 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer(TOGAR) | terminated | Phase 2 | 3 | Baylor College of MedicineOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion(LIDA-BII) | terminated | Phase 2 | 44 | University Hospital, MontpellierOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05131776 | EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma. | terminated | Phase 2 / Phase 3 | 2 | Chinese University of Hong KongOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03301454 | Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer(E-DIS2) | terminated | Phase 2 | 15 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners(NeuroPrevPTSD) | terminated | Phase 2 | 19 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04166383 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04327700 | Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03785210 | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | terminated | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05983367 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | terminated | Phase 2 | 76 | Inspirna, Inc.INDUSTRY | 3 | Feb 20, 2026 | clinicaltrials |
| NCT06851104 | A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence | terminated | Phase 2 | 45 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02738606 | Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery | terminated | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05442749 | Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer(PARPi-PANC) | terminated | Phase 2 | 2 | Centre Leon BerardOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT05733611 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | terminated | Phase 2 | 5 | Replimune, Inc.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT06739252 | Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA | terminated | Phase 2 | 1 | Peking UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | TakedaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06006923 | Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer | terminated | Phase 2 | 1 | Anwaar SaeedOTHER | 1 | Jan 20, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials